|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.73 USD | -0.80% |
|
+6.10% | +24.76% |
| 07-14 | Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing | MT |
| 06-25 | Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing | MT |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,769 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 27.84% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 3,148 | 3,510 | 3,389 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 52.34% | 11.5% | -3.44% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -8.16x | -8.89x | -10.4x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 19.8x | -18.3x | 19.7x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.7x | 1.08x | 0.7x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 44.3x | 40.5x | 22.5x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 37x | 37.7x | 20.2x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -6.67x | -7.72x | -11.9x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.39x | -7.26x | -7.31x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -12.2x | -10.5x | -17.8x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -8.21% | -9.5% | -5.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.675 | -3.372 | -2.885 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 85.06 | 93.06 | 167.8 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -472.1 | -454.5 | -285.6 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -492.6 | -483.2 | -463.6 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -456.4 | -430.5 | -394.5 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -621.3 | -259.3 | -379.9 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 29.97 | 29.97 | 29.97 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 125,773 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 21/02/24 | 25/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.16x | 37.01x | -6.67x | -.--% | 3.77B | |
| 31.99x | 5.69x | 17.6x | 1.03% | 46.06B | |
| -22.96x | 333.54x | -20.89x | -.--% | 38.91B | |
| 48.28x | 4.86x | 31.12x | -.--% | 35.57B | |
| 24.16x | 2.71x | 11.7x | -.--% | 33.13B | |
| 26.27x | 7.71x | 19.36x | 0.43% | 26.42B | |
| 31.03x | 5.02x | 22.85x | -.--% | 15.08B | |
| 24.17x | 2.07x | 9.1x | 1.09% | 14.08B | |
| 23.64x | 1.89x | 11.43x | -.--% | 12.81B | |
| Average | 19.83x | 44.50x | 10.62x | 0.28% | 25.09B | |
| Weighted average by Cap. | 21.58x | 61.89x | 11.50x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
